Orphan medical devices: addressing the regulatory and access gaps in the EU and US. [PDF]
Akodad S, Haon B, Rochaix L, Stevens H.
europepmc +1 more source
Medicine Development and Access for Rare Diseases: Can We Do Better? [PDF]
Hollak CEM +14 more
europepmc +1 more source
Priced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States. [PDF]
Alperin C, Nguyen N, Duffey M, Clark EH.
europepmc +1 more source
Methodological challenges in Dutch HTA of non-oncological orphan drugs: a retrospective analysis and price comparison using different pricing models. [PDF]
Walraven J, Kaveh M, Uyl-de Groot C.
europepmc +1 more source
Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983-2022. [PDF]
Wang S +11 more
europepmc +1 more source
Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023. [PDF]
Bouwman L +3 more
europepmc +1 more source
Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA. [PDF]
Höger P +8 more
europepmc +1 more source
Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug. [PDF]
Shahid SR +4 more
europepmc +1 more source
Informing Dose for Pediatric Rare Diseases-A Survey of Recent Orphan Drugs Approvals. [PDF]
Fletcher EP +6 more
europepmc +1 more source
Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China. [PDF]
Shi J, Hu H, Ung COL.
europepmc +1 more source

